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Abstract 
Background: Day 7 plasma concentrations of lumefantrine (LF) can serve as a marker to predict malaria treatment 
outcome in different study populations. Two main cut-off points (175 and 280 ng/ml) are used to indicate plasma 
concentrations of LF, below which treatment failure is anticipated. However, there is limited data on the cumula-
tive risk of recurrent parasitaemia (RP) in relation to day 7 LF plasma concentrations in pregnant women. This study 
describes the prevalence, severity, factors influencing treatment outcome of malaria in pregnancy and day 7 LF 
plasma concentration therapeutic cut-off points that predicts treatment outcome in pregnant women.
Methods: This was a one-arm prospective cohort study whereby 89 pregnant women with uncomplicated Plasmo-
dium falciparum malaria receiving artemether-lumefantrine (ALu) participated in pharmacokinetics and pharmacody-
namics study. Blood samples were collected on days 0, 2, 7, 14, 21 and 28 for malaria parasite quantification. LF plasma 
concentrations were determined on day 7. The primary outcome measure was an adequate clinical and parasitologi-
cal response (ACPR) after treatment with ALu.
Results: The prevalence of malaria in pregnant women was 8.1 % (95 % CI 6.85–9.35) of whom 3.4 % (95 % CI 
1.49–8.51) had severe malaria. The overall PCR-uncorrected treatment failure rate was 11.7 % (95 % CI 0.54–13.46 %). 
Low baseline hemoglobin (<10 g/dl) and day 7 LF concentration <600 ng/ml were significant predictors of RP. The 
median day 7 LF concentration was significantly lower in pregnant women with RP (270 ng/ml) than those with ACPR 
(705 ng/ml) (p = 0.016). The relative risk of RP was 4.8 folds higher (p = 0.034) when cut-off of <280 ng/ml was com-
pared to ≥280 ng/ml and 7.8-folds higher (p = 0.022) when cut-off of <600 ng/ml was compared to ≥600 ng/ml. The 
cut-off value of 175 ng/ml was not associated with the risk of RP (p = 0.399).
Conclusions: Pregnant women with day 7 LF concentration <600 ng/ml are at high risk of RP than those 
with ≥600 ng/ml. To achieve effective therapeutic outcome, higher day 7 venous plasma LF concentration ≥600 ng/
ml is required for pregnant patients than the previously suggested cut-off value of 175 or 280 ng/ml for non-pregnant 
adult patients.
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Background
Over 93  % of the Tanzania mainland population lives 
in areas where malaria is endemic. In Tanzania, there 
is great variation in the risk of malaria transmission 
and prevalence ranging from 1–33  %, with an average 
of about 10 % [1]. The levels of transmission are high in 
Lake zone regions, coastal regions and southern lowlands 
[2]. Despite declining of malaria prevalence in the coun-
try, recent reports show that malaria cases range between 
10–12 million annually and is still a leading cause of out-
patient, inpatient and hospital deaths with 60–80 thou-
sands estimated death per year [2]. Pregnant women and 
children under 5 years of age are at high risk for malaria 
infections. The risk of malaria infection in pregnant 
women increases due to changes in hormonal levels and 
immune system [3]. In high-transmission settings, the 
adverse effects of Plasmodium falciparum infection in 
pregnancy are most pronounced for women in their first 
pregnancy whereas in low transmission settings malaria 
affects all pregnant women, regardless of the number of 
times they have been pregnant [4]. It is estimated that 1.7 
million pregnant women in Tanzania mainland are sus-
ceptible to malaria infection per year. The overall preva-
lence of malaria parasitaemia among pregnant women 
residing on Lake zone regions was 12.2 % (95 % CI 11.5–
12.8) [5].
Artemisinin-based combination therapy is recom-
mended by WHO as first-line treatment for uncom-
plicated P. falciparum malaria in the second and third 
trimester of pregnancy [6]. The fixed dose drug com-
bination of artemether and lumefantrine (ALu) is the 
first-line drug of choice to treat malaria in Tanzania 
[7]. Artemether is short-acting and has a very rapid and 
potent anti-malarial effect, resulting into prompt resolu-
tion of symptoms. The drug has a short half-life (1–3 h) 
and is rapidly metabolized into an active metabolite—
dihydroartemisinin. Artemether and its active metabo-
lite have been estimated to reduce parasite biomass by 
approximately 10,000-fold per reproductive cycle (every 
2  days) [8]. Lumefantrine (LF) is long-acting and has 
longer elimination half-life killing nearly all residual par-
asites. Combining short and long acting drugs ensures 
clearance of all P. falciparum parasites and prevents 
recrudescence, thereby ensuring malaria cure [9].
Plasma LF concentrations at day 7 reflects the degree 
to which the residual parasites are exposed, and is gen-
erally considered as a useful pharmacokinetic marker 
to predict malaria treatment outcome [10, 11]. Differ-
ent ‘therapeutic’ cut-off points of day 7 LF concentra-
tions have been suggested ranging from 170–600  ng/
ml below which treatment failure is anticipated for dif-
ferent study populations [10–18]. Therapeutic cut-offs 
points of 175  ng/ml [11], and 280  ng/ml [19] are the 
most commonly used. The relative risk of recrudes-
cent malaria has been reported to be substantially 
higher in patients with day 7 concentrations at the cut-
off point  <175  ng/ml compared to those with higher 
concentration [11]. Day 7 plasma LF concentration 
of <280 ng/ml in Thai patients resulted in 51 % cure rate 
compared to 75 % cure rates in patients with concentra-
tion >280 ng/ml [19]. A recent pharmacokinetics study 
of mefloquine, piperaquine and ALu in Cambodia and 
Tanzania reported that the targeted day 7 LF concentra-
tion (>600 ng/ml) was not achieved in 100 (71 %)—non-
pregnant adult patients [20]. The study reported that 
in Tanzania, 35 % of samples obtained from non-preg-
nant population had LF concentration below the cut off 
value of <175 ng/ml at day 7 [20]. Pregnancy is known 
to lower blood concentrations of artemether and LF, 
thus putting pregnant women at risk of under-dosing 
[20–22].
Malaria during pregnancy is associated with high 
maternal and perinatal mortality [6]. Pregnancy is an 
important factor affecting the pharmacokinetics of a 
number of drugs including anti-malarial drugs mainly 
due to reduced drug absorption, elevated drug metabo-
lism, and rapid clearance rate and altered volume of dis-
tribution [23]. Activity of CYP3A4, the main enzyme 
responsible for LF metabolism, is increased during preg-
nancy [24]. Studies have reported lower venous plasma 
LF concentrations at day 7 in pregnant women compared 
with those in non-pregnant women [23, 25, 26]. Large 
proportion (30–40 %) of pregnant patients displayed day 
7 plasma LF concentration below 280 ng/mL [13, 20, 22]. 
Sub-therapeutic plasma drug exposures may select for 
parasites with reduced drug susceptibility and increases 
the risk for development of drug resistance. Indeed, a 
higher treatment failure rate has been observed for preg-
nant women compared to non-pregnant women living in 
the same area [13, 22, 23, 27].
It is well recognized that plasma LF concentration on 
day 7 LF levels is a surrogate marker to predict treat-
ment outcome, but the therapeutic cut of point may vary 
between different patient populations and transmission 
areas (low versus high). The therapeutic day 7 LF con-
centration threshold below which RP is anticipated needs 
to be defined better, particularly for high risk group liv-
ing in malaria endemic countries [14], including preg-
nant women whose pharmacokinetic profile is altered 
due to pregnancy associated hormonal and physiological 
changes [28, 29]. Therefore, the aim of this study was to 
describe (i) malaria prevalence, severity and treatment 
outcome in pregnancy, and (ii) to describe the day 7 LF 
plasma concentration profile and identify its optimal 
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therapeutic cut-off point which predicts malaria treat-
ment outcome in pregnant women.
Methods
Study design and procedures
This was a one-arm prospective cohort study that 
included all pregnant women who gave consent to be 
screened for malaria when attending antenatal clinics [30] 
at Kisarawe and Mkuranga district hospitals, northern 
Tanzania. In this region transmission of malaria is peren-
nial, which peaks by the end of the long and short rains 
from May to July and December to January, respectively. 
The prevalence of asexual parasitaemia in this area is 
14 %, and P. falciparum is the predominant species [31].
The study received ethics approval from the institu-
tional review board of Muhimbili University of Health 
and Allied Sciences (MUHAS). Participants were 
informed about the aim of the study and gave written 
consent before participating in the study. Confidential-
ity was ensured to all individuals who participated in the 
study, whereby, all collected samples and the filled con-
fidential report forms (CRF) have a coded identification 
number.
Sample size
The study aimed to obtain a sample size of 50, which is 
the minimum recommended by the WHO regardless of 
rates of failure anticipated, in order to be representative 
[32]. This is the first observational study to determine 
the prevalence of malaria in pregnant women from Tan-
zania and could only include malaria cases available by 
screening all pregnant women attending antenatal care at 
the study sites. Considering anticipated population pro-
portion of clinical failures in pregnant women (P) being 
18 % [23], with 95 % confidence level and 10 % precision, 
a minimum sample size of 50 would be needed. Add-
ing a 20 % loss to follow the required sample size was 59 
malaria positive pregnant women.
Patients recruitment
Between May 2014 to April 2015, 1835 pregnant women 
attending the antenatal cares (ANCs) were screened by 
using malaria rapid diagnostic test (MRDT). Pregnant 
women with MRDT positive results were enrolled in the 
study. Inclusion criteria included women aged 18  years 
and above, resident of Mkuranga or Kisarawe districts, in 
the second or third trimester, with uncomplicated P. fal-
ciparum infection and haemoglobin level of >8 g/dl. Full 
medical history, including current illnesses and medica-
tion used, were recorded. Clinical examination on the 
day of enrollment and during follow-up visits on days 2, 
7, 14 and 28 were done including axillary temperature 
measurement and malaria-related symptoms evaluation.
Screening of pregnant women for malaria
Malaria was tested by using SD BIOLINE Malaria Ag 
P.f/Pan® MRDT (Standard Diagnostics, Inc, Korea). The 
blood samples were collected by finger prick. About 
5 μl of whole blood were added into the ‘sample well’ of 
respective test devices using a micropipette supplied with 
the test kit. Four drops of assay diluent were added into 
the ‘sample diluent well’. All the test results were recorded 
within 30 min. The sample was positive when there was 
appearance of a control line and a test line on the result 
window but it was negative when there was only a control 
line.
Drug regimen
Enrolled study participants received four tablets of ALu 
(Coartem; Novartis Pharma AG, Basel, Switzerland) 
(20  mg artemether and 120  mg lumefantrine) over the 
course of 3 days at 0, 8, 24, 36, 48, and 60 h. In order to 
enhance absorption of ALu and standardize dose admin-
istration, patients were supplied with packets of milk 
containing 4.5 g of fat [33] and were instructed to swallow 
ALu tablets with 200 mls of milk. Patients were directed 
on how to take the remaining five doses of the drug at 
home and were asked to come to the hospital to take the 
last dose. Patients with microscopically-confirmed P. fal-
ciparum within 28  days of follow-up were treated with 
either artesunate or artemether or quinine injection as 
per the national malaria treatment guidelines [5] since 
this was presumptively regarded as treatment failure.
Microscopy and haemoglobin determination
To estimate the parasite density, capillary blood from 
a finger prick was taken at days 0, 2, 7, 14, 21 and 28. 
Samples were collected on slides, Giemsa-stained thick 
smears were examined by two different experienced 
microscopists using light microscope. Plasmodium para-
sites were counted against 200 white blood cells (WBC) 
on the thick film. Five hundred WBCs were counted 
where less than ten parasites were observed. The para-
site count was then multiplied by a factor of 40 or 16 
depending on the counted WBCs. Haemoglobin was 
measured by HemoCue Hb 201 + ® machine (HemoCue 
AB Ängelholm, Sweden) following manufacturers’ 
instructions.
Quantification of plasma LF concentrations
In total, three millilitres of venous blood were drawn 
from the patients at random times on days 0 and 7 to 
determine plasma LF concentrations. Day 0 blood sample 
was collected before starting the medication as a baseline 
in order to determine the presence of LF in the patient’s 
plasma prior to treatment [34, 35]. Blood samples in hep-
arinized vacutainer tubes were centrifuged at 2000 g for 
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5 min, and the plasma samples were stored in cryotubes. 
Samples were stored at −80 °C at MUHAS before analy-
sis. Plasma LF concentration was analysed using a vali-
dated high performance liquid chromatography (HPLC) 
with ultraviolet detection at Sida/MUHAS bioanalytical 
laboratory in Dar-es-Salaam, Tanzania as described pre-
viously [36]. The coefficients of variation (CV %) during 
the analysis of LF were 8.4, 4.7 and 4.5  % at 100, 1000, 
and 8000 ng/ml, respectively. The lower limit of quantifi-
cation was 50 ng/ml.
Malaria treatment outcome
Treatment outcome classification was based on WHO 
recommendations on the methods for surveillance of 
anti-malarial drug efficacy as early treatment failure 
(ETF), late clinical failure (LCF), late parasitological 
failure (LPF), and Adequate clinical and parasitological 
response (ACPR) [32]. An ACPR in patients at day 28 
after anti-malarial drug treatment was the primary study 
objective. The time to recurrent parasitaemia (RP) or the 
risk of RP was defined as the number of days between 
taking the first dose of ALu and the day of microscopi-
cally detecting malaria parasites in the thick blood film. 
The time at risk ended whenever one of the following 
conditions occurred: RP, loss to follow-up, withdrawal, or 
end of follow-up period [37].
Data analysis
The data were analysed using the statistical package for 
social sciences (SPSS—IBM Corporation, Somers, NY) 
software, version 20. The intention-to-treat approach was 
used to analyse the anti-malarial treatment response. All 
day 7 LF plasma concentrations were first transformed 
into log 10 values before applying parametric tests. The 
relation of the outcome variable (treatment outcome) 
and explanatory variables were tested using independ-
ent t test (log plasma LF day 7 concentrations, age of the 
patient, gestational age, gravidity and baseline parasite 
count). The cumulative risk of RP was estimated using 
the Kaplan–Meier product limit formula and data were 




Baseline characteristics of all enrolled patients are 
presented in Table  1. The mean age of pregnant 
patients was 24.96  ±  6 (range 16–38) years whereas 
the majority (44 %) were multigravidae and in the sec-
ond trimester (68.6  %). The median parasite density 
of the enrolled patients was 1400 (range 400–58,416) 
parasites/µl.
Malaria prevalence and its severity in pregnancy
One thousand eight hundred and thirty five pregnant 
women were screened using MRDT during the study 
period and out of these 148 were positive for malaria. 
Prevalence of malaria in pregnancy during the study 
period was 8.1  % (95  % CI 6.85–9.35). Out of these 
malaria positive pregnant women, 5 (3.4, 95 % CI 1.49–
8.51) had severe malaria and the rest (143 pregnant 
women) had uncomplicated P. falciparum infection. 
Severe malaria was prominent in primigravidae (four 
women) than multigravid pregnant women (one woman). 
MRDT positive samples were further analysed using 
microscope whereby, 111 out of 148 (75 %) samples were 
confirmed to have P. falciparum infection.
Eighty-nine patients with uncomplicated P. falcipa-
rum malaria consented and were enrolled in this study. 
Flowchart for study enrolment is presented in Fig. 1. In 
this study, seven (7.9 %) of the enrolled pregnant women 
were excluded from the data analysis due to detection 
of plasma LF concentration (>50 ng/ml) at baseline, and 
twelve (13.5  %) patients did not return to the ANCs to 
provide blood samples for determination of day 7 LF con-
centration. Therefore, sixty pregnant women were avail-
able to provide blood samples for the whole period of 
28 days follow up.
Malaria treatment outcome in pregnancy
There were a total of seven (11.7; 95 % CI 0.54–13.46 %) 
therapeutic failures in this study among pregnant 
women. No ETF or LCF was observed in this study; 
Table 1 Baseline characteristics of patients with P. falcipa-
rum malaria sampled for LF pharmacokinetics (n = 60)




 <20 16 26.7
 25–35 38 63.3
 >35 6 10.0
Gravida
 Primigravida 21 35
 Secundigravida 13 21.7
 Multigravida 26 43.3
Trimester
 Second 40 66.7
 Third 20 33.3
Parasitaemia
 <1000 20 33.3
 1000–10,000 33 55.0
 >10,000 7 11.7
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nonetheless, seven pregnant women had LPF. Hence, the 
overall ACPR after 28 days of follow up was 88.3 % (95 % 
CI 40.37–65.63 %).
Day 7 LF concentration was significantly lower 
among pregnant women with RP than those with ACPR 
(p = 0.016). The median plasma LF concentration among 
pregnant women with ACPR was 705  ng/ml (140–
3059 ng/ml), whereas for women with LPF, it was 270 ng/
ml (123.6–602  ng/ml) (Fig.  2). There was highly signifi-
cant association between baseline Hb levels (p = 0.003) 
Fig. 1 Patient recruitment flow chart for the malaria in pregnancy study in Kisarawe and Mkuranga Districts
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and day 7 LF plasma concentrations (p = 0.008) with RP. 
Other covariates, such as age, gravida, gestational age 
and baseline parasitaemia were not associated with RP 
(Table 2). 
Pregnant women with Hb <10 g/dl had 6.4-folds risk of 
RP than those with >10 g/dl whereas those with day 7 LF 
concentration <600 ng/ml had a 7.8-folds risk of RP than 
those with >600 ng/ml.
Day 7 LF plasma concentrations and malaria treatment 
outcome
Day 7 median plasma concentrations of LF after admin-
istration of a six-dose regimen over three days were 
650 ng/mL (Inter quartile range = 294–1195 ng/mL) for 
pregnant women. There was marked inter-individual var-
iability in day 7 plasma LF concentrations (range = 123–
3059  ng/mL, coefficient of variation  =  81.1  %). There 
was no association between day 7 LF plasma concentra-
tions with age (p =  0.784), gravida (p =  0.314), trimes-
ter (p  =  0.496) or baseline parasitaemia (p  =  0.644). 
Amongst of the studied population 6.7 % of the patients 
had day 7 concentrations below the therapeutic cut-
off of 175  ng/ml, 21.7  % below 280  ng/ml, and 43.3  % 
below 600 ng/ml. More than half of the pregnant women 
(57  %) had day 7 concentration of  >600  ng/ml which 
is required for maximal efficacy. Equally, 15  % had 
175–280 ng/ml, and 21.7 % had 281–600 ng/ml (Fig. 3). 
Treatment outcome in relation to day 7 LF plasma lev-
els in pregnant women was such that ACPR was 75, 66.7, 
76.9 and 97.1  % when day 7 LF plasma concentrations 
were <175, <280, <600 and >600 ng/ml, respectively.
Independent t-test indicated highly significant associa-
tion between high log day 7 plasma LF concentrations 
and ACPR (p  =  0.008). The relative risk of RP was 2.3 
(when comparing LF concentrations  <175 to  >175  ng/
ml), 4.8 (when comparing LF concentrations  <280 
to >280 ng/ml) and 7.8-folds higher when comparing LF 
concentrations < 600 to >600 ng/ml. The relative risk of 
RP in patients at the cut-off point LF <175 ng/ml was not 
significantly higher than in those with LF concentration 
of  >175  ng/ml (p =  0.399). On the other hand, relative 
Fig. 2 Comparison of day 7 plasma LF concentration in pregnant 
women with adequate clinical and parasitological response (CURED, 
n = 54) versus those with late treatment failure (LTF, n = 7) after 
treatment with ALu by day 28 using independent t test. Data was 
converted to log 10 value before analysis
Table 2 Analysis of  predictors of  malaria treatment out-
come in pregnant women
Characteristic Mean (95 % CI) P value
Age (years)
 RP 25.7 (21.3–30.1) 0.889
 ACPR 25.36 (23.57–27.14)
Gravida
 RP 2 (1–3) 0.529
 ACPR 3 (2–3)
Gestation age
 RP 22 (19–24) 0.714
 ACPR 23 (21–24)
Baseline parasitaemia
 RP 3960 (1464.4–9384.4) 0.502
 ACPR 2688 (1443.0–3933.6)
Baseline Hb (g/dl)
 RP 8.87 (8.11–9.64) 0.003
 ACPR 10.33 (10.00–10.67)
Day 7 LF levels (ng/ml)
 RP 2.46 (2.23–2.68) 0.008




























Day 7 LF concentar	on (ng/ml) 
Fig. 3 Day 7 LF concentrations for pregnant women treated for 
malaria (n = 60)
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risk of RP was statistically significant using the LF cut-off 
point of <280 ng/ml compared to >280 ng/ml (p = 0.034) 
and  <600  ng/ml compared to  >600  ng/ml (p  =  0.022) 
(Table 3).
Kaplan–Meier analysis of the PCR uncorrected data 
following treatment of uncomplicated malaria in preg-
nant women showed that there was no cumulative risk 
of RP regardless of day 7 LF concentration until on day 
7 after the administration of the first dose of ALu. When 
the cut-off value was 280 ng/ml, the cumulative risk of RP 
was slightly increased on day 7 in patients with LF con-
centration >280 ng/ml than those with <280 ng/ml up to 
day 14. After that, the cumulative risk of RP was increas-
ing with increase in follow up period in patients with LF 
concentration  <280  ng/ml than those with  >280  ng/ml 
(log-rank p  <  0.019). Using the cut-off value of 600  ng/
ml, the cumulative risk of RP was increasing in patients 
with <600 ng/ml from day 7 onwards, whereas, there was 
a slight increase on the cumulative risk of RP on day 14 
in patients with LF concentration  >600  ng/ml (log-rank 
p < 0.017) (Fig. 4).
Discussion
This study describes the prevalence of malaria in preg-
nancy, its severity and treatment outcome, risk factors 
for RP and the therapeutic threshold of day 7 LF plasma 
concentrations that predict treatment outcome in preg-
nant women from Tanzania. Few studies investigated 
the LF plasma concentration and treatment outcome in 
pregnant women previously [13, 22, 23, 38]. The present 
study, differs from previous studies by describing preva-
lence of malaria in pregnancy, its severity and risk of RP 
at three different day 7 plasma LF concentration thera-
peutic cut-off points, namely <175, <280, and <600 ng/ml 
to predict malaria treatment failure in pregnant women. 
The cut-off value of 175 or 280 ng/ml in order to achieve 
effective therapeutic outcome and 600 ng/ml for maximal 
efficacy has previously been proposed in studies of non-
pregnant adult patients [11, 13]. Altered LF pharmacoki-
netic properties contributing to the high rates of failure 
of ALu treatment in later pregnancy is reported previ-
ously [14, 22]. Accordingly the suggested plasma LF con-
centration cut-off points to predict maximal efficacy in 
non-pregnant adult may not hold true during pregnancy. 
The present study explored which optimal cut-off value 
would be pertinent to predict efficacy in malaria infected 
pregnant women using the proposed reference cut off 
points for non-pregnant adult patients. In line with the 
hypothesis of the study and the findings, a recent system-
atic review indicated low day 7 plasma concentrations is 
commonly seen in LF studies in pregnant women. This 
indicates low exposure and possibly reduced efficacy and 
hence a need for dose optimization to ensure the highest 
possible efficacy of malaria treatment in pregnant women 
[21, 22].
Results from this study indicate that 148 (8.1 %) preg-
nant women were MRDT positive of whom 111 (6.0 %) 
had parasitologically-proven P. falciparum malaria that 
was confirmed and quantified by microscopy. This figure 
is lower compared to the prevalence of malaria in preg-
nancy reported in Lake Zone regions which was 12.2 % 
[5]. The prevalence of 8.1  % malaria in pregnancy from 
Table 3 Comparison of relative risk of RP in relation to day 
7 LF cut-off plasma concentration in pregnant women
Day 7 LF cut-off  
conc. (ng/ml)
RR 95 % CI P value (Fischer’s 
exact test)
<175 to >175 2.3 0.36–14.96 0.399
<280 to >280 4.8 1.23–18.88 0.034
<600 to >600 7.8 1.00–61.22 0.022
Fig. 4 Kaplan Meier curve showing cumulative risk of RP in pregnant 
women with cut-off day 7 LF plasma concentration of <280 ng/
mL compared to >280 ng/mL (Top) versus <600 ng/mL compared 
to >600 ng/mL (below). P value is from log rank test
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Tanzania is comparable to other reports in pregnant 
women from East Africa region such as (9.1 % in Ethiopia 
[39] and South Sudan [40]), but lower than reports from 
West Africa (7.7–42 % from Nigeria [41, 42] and 18.1 % 
from Burkina Faso [43]). Marked decline in the preva-
lence of malaria in pregnant women from Kenya, as a 
result of malaria control measures often targeting preg-
nant women attending ANCs is reported [40]. Baseline 
epidemiological data from the present study also pro-
vides relevant information for policy makers to properly 
assess the impact of malaria control programme in preg-
nant women living in Tanzania and sub-Sahara Africa.
The study is well controlled, by excluding data from 
study participants in whom plasma LF concentration was 
detected at baseline (day 0). Residual anti-malarial con-
centrations before treatment in patients with malaria may 
interfere with outcome of the treatment under investiga-
tion and creates bias in drug safety and efficacy assess-
ment [34, 35]. A previous study from Tanzania indicated 
that more than half (54.1  %) of patients reporting no 
anti-malarial intake within the last 28  days, had plasma 
LF concentration above the lower limit of detection [35]. 
In this study, 7 (8  %) pregnant women had baseline LF 
concentration >50 ng/mL, indicating drug intake within 
the last 28 days prior to treatment. Thus data from these 
patients was excluded during analysis. Based on WHO 
guidelines on ‘Methods for surveillance of anti-malarial 
drugs efficacy’, a follow-up of 28 days is recommended as 
the minimum duration for medicines with elimination 
half-lives of less than 7 days (including LF) [44]. A longer 
study follow-up would have increased the risk that more 
patients (pregnant women) will be lost to follow-up, 
reducing the study’s validity and sensitivity.
Pharmacokinetics of drugs in pregnancy is altered 
by several factors, including physiological changes that 
lower drug absorption, speed up drug clearance, and 
increase body fluid volume of distribution [28, 29, 45]. 
In this study, the median day 7 plasma LF concentration 
(650  ng/mL) found in pregnant women is comparable 
to previous reports from adult malaria patients in Tan-
zania (641.4 ng/mL) [46]. The model based prediction of 
median day 7 LF concentration by Mosha et al. for Tan-
zanian pregnant (908 ng/mL) and non-pregnant patients 
(1382 ng/mL) [23] are relatively higher than the findings 
from pregnant women and other reports for adult popu-
lation from the same region [46]. The observed high con-
centrations that have been previously reported within 
the same region can be due to administration of the anti-
malarial drug under direct observed therapy (DOT) [23].
As many as 43.3 % pregnant women did have day 7 LF 
concentrations of  <600  ng/ml which is slightly higher 
than 31 % which was previously reported in a study con-
ducted by Mosha et al. in Rufiji, Coast region in Tanzania 
[23]. Moreover, 6.7 and 15 % of pregnant women in this 
study had day 7 LF plasma concentrations below the pre-
viously defined therapeutic cut-offs of 175 ng/ml [11] and 
280  ng/ml [19], respectively. These findings are similar 
to those reported in Uganda but slightly higher to those 
reported in a previous study in Tanzania [23].
The cure rate in this study was 88.3 %, which is similar 
to previous report from Rufiji, Tanzania [23]. The median 
LF concentration on day 7 in patients with RP was sig-
nificantly lower compared to those with ACPR. Stud-
ies have suggested that in order to improve therapeutic 
efficacy, dose adjustment especially in pregnant women 
should be taken into consideration to enable a higher 
day 7 LF concentrations which has been shown to be a 
marker of treatment outcome [23, 47]. Using population-
modeling approach, Mosha et al. predicted lower median 
venous plasma LF concentrations at day 7 and high 
treatment failure in pregnant women compared to non-
pregnant women [23]. However studies from Uganda 
reported a minimal alteration of LF pharmacokinetics 
between pregnant and non-pregnant patients, which 
was not significant [47, 48]. Thus in the era of emerging 
drug resistance, further studies with a larger sample size 
are urgently needed to optimize anti-malarial efficacy 
in pregnant women, particularly in high transmission 
regions.
The relative risk of RP increased proportionately 
when day 7 LF concentration cut-off values increased 
from  <175 to  <600  ng/ml. The host immune responses 
are reduced during pregnancy and this potentially 
means that a different LF day 7 concentration thresh-
old is required in this special population [26]. The rela-
tive risk of RP was 7.8-folds higher with the cut-off point 
of  <600  ng/ml as compared to  >600  ng/ml (2.3 and 4.8 
at the cut-off points of <175 and 280 ng/ml, respectively) 
(Fig.  4). Therefore the use of the cut-off points of  <175 
or  <  280  ng/ml may be underestimating the cumulative 
risk of RP among pregnant women by excluding other 
patients at risk with LF concentration  >280  ng/ml. The 
findings are in line with previous reports from Thailand 
where day 7 LF concentration above 600 ng/ml was asso-
ciated with 100 % efficacy in pregnant women [14].
In areas of high or moderate malaria transmission, 
response to malaria treatment mainly depends on the 
host’s immunity, genetic and the amount of drugs avail-
able in human plasma to clear the parasites [49, 50]. 
The study area could be categorized as holoendemic 
or moderate malaria transmission area. Despite a high 
number of patients with day 7 LF plasma concentration 
of <600 ng/ml (45 %), the therapeutic failure rate (11.7 %) 
in pregnant women in this study was much lower than 
16–30  % which was reported in Thailand in 2009 [14, 
22]. High cure rates observed in East Africa can be due to 
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the immunity obtained in population living in moderate 
to high malaria transmission areas [23, 25, 51]. Moreo-
ver lower cure rates in Thai pregnant women can be 
due to higher levels of drug resistance. Prolonged expo-
sure of anti-malarial drugs at sub-therapeutic levels may 
select for parasites with reduced drug susceptibility and 
increase the risk for development of drug resistance.
Other baseline characteristics, such as age of the 
patient, gravida, trimester and baseline parasitaemia 
were not important factors determining the day 7 LF 
concentration and subsequent therapeutic response 
in study participants. This is contrary to what has been 
reported in a previous study involving pregnant and non-
pregnant patients in which patients with higher baseline 
parasitaemia were more likely to fail treatment [14].
Conclusions
The findings of this study support that day 7 LF concen-
trations can be used as a reliable predictor of treatment 
outcome of malaria in pregnant women. The relative and 
cumulative risk of RP is higher when using the cut-off 
point of  <600  ng/ml as compared to the previous cut-
off points of  <175 and  <280  ng/ml indicating that even 
pregnant women with day 7 LF concentrations >280 ng/
ml but less than 600 ng/ml are still at high risk of RP. In 
order to achieve effective therapeutic outcome, higher 
day 7 venous plasma LF concentration  ≥600  ng/ml is 
required in pregnant patients for maximal efficacy than 
a cut-off value of 175 or 280 ng/ml, which has been sug-
gested for non-pregnant adult patients. More studies in 
different areas should be conducted because malaria 
treatment outcome after ALu administration can be 
influenced by a number of other factors besides day 7 LF 
concentration.
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